Discovery of new Syk inhibitors through structure-based virtual screening

Bioorg Med Chem Lett. 2017 Apr 15;27(8):1776-1779. doi: 10.1016/j.bmcl.2017.02.060. Epub 2017 Feb 24.


Spleen tyrosine kinase (Syk) is an attractive target for the discovery of new treatments for inflammatory and autoimmune disorders. Structure-based virtual screening was performed for identifying novel scaffolds of Syk inhibitors. A total of 16 hits were discovered in the enzyme assay and 8 compounds had an IC50 value lower than 10μM. In particular, compound 11 (IC50=3.2μM) was active in the cellular Syk assay and could inhibit lymphocytes proliferation in a dose-dependent manner, which could be used as a good starting point for the discovery of new class of Syk inhibitors.

Keywords: Indazole-3-carboxamide inhibitor; Spleen tyrosine kinase; Virtual screening.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Autoimmune Diseases / drug therapy
  • Cell Line
  • Cell Proliferation / drug effects
  • Humans
  • Indazoles / chemistry*
  • Indazoles / pharmacology*
  • Inflammation / drug therapy
  • Lymphocytes / cytology
  • Lymphocytes / drug effects
  • Lymphocytes / enzymology
  • Molecular Docking Simulation
  • Protein Kinase Inhibitors / chemistry*
  • Protein Kinase Inhibitors / pharmacology*
  • Syk Kinase / antagonists & inhibitors*
  • Syk Kinase / metabolism


  • Indazoles
  • Protein Kinase Inhibitors
  • Syk Kinase